NCT05729373: An ongoing trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial is ongoing. It must report results 9 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05729373 |
|---|---|
| Title | A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 8, 2023 |
| Completion date | Sept. 26, 2025 |
| Required reporting date | Sept. 26, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |